MarketResearchReports.Biz
announces addition of new report"
Gastric and Gastroesophageal Junction Adenocarcinoma - US Drug
Forecast and Market Analysis to 2024 "to
its database.
Gastric
and gastroesophageal junction adenocarcinoma
(G/GEJAC) represents the majority of gastric cancer cases worldwide.
It is the fifth most diagnosed cancer globally, and the third most
common cause of cancer death in the world. The major treatments for
G/GEJAC are chemotherapy-based, but targeted therapies such as HER2
and angiogenesis inhibitors have been approved and are being added to
chemotherapy regimens since 2010 and 2014, respectively.
The
US is a large G/GEJAC market due to high treatment rates of advanced
diseases and higher drug prices than in the rest of the 8MM.
Increased sales of G/GEJAC therapies over the forecast period will be
driven by increasing disease incident cases, the rapid uptake of
newly approved Cyramza, and the approval and increasing uptake of
expensive pipeline agents, such as anti-PD-1 immunotherapies and a
HER2-targeted therapy.
Download
Sample copy of this Report @
Scope
- Overview of G/GEJAC including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the
key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the US from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting the US G/GEJAC
market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for G/GEJAC.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in US.
Table
of Content :
1.1
List of Tables
1.2
List of Figures
2
Introduction
2.1
Catalyst
2.2
Related Reports
2.3
Upcoming Related Reports
3
Disease Overview
3.1
Etiology and Pathophysiology
3.1.1
Etiology
3.1.2
Pathophysiology
3.1.3
Biomarkers/Targets of Interest
3.2
Staging
3.3
Symptoms
3.4
Prognosis
3.5
Quality of Life
4
Disease Management
4.1
Diagnosis and Treatment Overview
4.1.1
Screening
4.1.2
Diagnosis
4.1.3
Treatment Guidelines and Leading Prescribed Drugs
4.1.4
Clinical Practice
4.2
US
4.2.1
Screening and Diagnosis
4.2.2
Clinical Practice
5
Competitive Assessment
5.1
Overview
5.2
HER2-Targeted Therapy
5.2.1
Herceptin (trastuzumab)
5.3
Angiogenesis Inhibitors
5.3.1
Cyramza (ramucirumab)
5.3.2
Aitan (apatinib)
5.4
Chemotherapies
5.4.1
TS-1 (tegafur, gimeracil, oteracil)
5.4.2
Abraxane (nab-paclitaxel)
6
Unmet Need and Opportunity
6.1
Overview
6.2
First-Line Therapy for HER2-Negative Patients
6.2.1
Unmet Need
6.2.2
Gap Analysis
6.2.3
Opportunity
6.3
New Molecular Targets for Targeted Therapies
6.3.1
Unmet Need
6.3.2
Gap Analysis
6.3.3
Opportunity
6.4
Effective Perioperative and Postoperative Therapies
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment